The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Molnupiravir, a repurposed flu antiviral with a poor history, delivers in a pivotal study in Covid-19 outpatients.
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.